Clin2
NCT07487441Possibly a fitNot yet recruiting

Sotatercept study for pulmonary hypertension

Pulmonary Arterial Hypertension (PAH)Pulmonary Hypertension

Part of Heart & circulation, Lungs & breathing clinical trials.

This study looks at how the drug sotatercept affects blood vessels in the lungs. It may help people with group 1 pulmonary hypertension (high blood pressure in the lungs).

Summary written for real people, not researchers, by Clin2.

Phase
N/A
Enrollment
30 people
Ages
18 years to 65 years
Study type
Observational

Who can take part

  • You must be 18 years or older.
  • You must have group 1 pulmonary hypertension (certain types).
  • You cannot have taken sotatercept before.
  • Your doctor must confirm it's safe for you to have a heart catheterization.
  • You must not be pregnant, and your blood counts and kidney function must be in a safe range.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07601295Not yet recruiting· Phase 2
Tiprelestat added to PAH treatment (Phase 2)

This trial tests whether adding a new drug called tiprelestat to standard pulmonary arterial hypertension (PAH) treatments can help patients breathe better and feel stronger. You'd receive tiprelestat or placebo along with your current PAH medications.

Tucson, Arizona
NCT06658522Recruiting· Phase 4
Sotatercept for right heart function in pulmonary hypertension

This study tests a medicine called sotatercept to see if it can improve how the right side of your heart pumps in people with PAH. It may help you feel better and slow down the disease.

Amsterdam, North Holland
NCT06751082Recruiting
Sotatercept for pulmonary hypertension study

This study looks at how well the drug Sotatercept works for people with pulmonary hypertension (high blood pressure in the lungs) in a real-world clinic setting. If you are already taking Sotatercept, you may be able to join.

Rochester, Minnesota
NCT07357974Not yet recruiting· Phase 1/Phase 2
Sotatercept for PAH imaging study

This trial tests a new medicine called sotatercept to see if it improves heart and lung blood vessel health in people with PAH. Participants will have special PET scans to measure changes.

Brest, Finistere
NCT07266519Not yet recruiting· Phase 2
Three-drug combo for new pulmonary arterial hypertension

This trial tests a combination of three medications (an endothelin receptor antagonist, a PDE5 inhibitor, and sotatercept) as the first treatment for people newly diagnosed with pulmonary arterial hypertension (PAH). It aims to see if starting with all three together works better than the usual approach.

NCT06941441Recruiting· Phase 3
Exercise and medicine study for pulmonary arterial hypertension

This trial tests whether adding the study drug sotatercept to your current PAH therapy along with a home exercise program can help you feel better and be more active. It's for people with certain types of PAH who are stable on their current treatment.

Seattle, Washington

Hear when a new Pulmonary Hypertension trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.